Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.18632/oncotarget.24353 http://scihub22266oqcxt.onion/10.18632/oncotarget.24353 C5884665!5884665!29644010     free     free     free       Oncotarget 2018 ; 9 (21): 15792-815 Nephropedia Template TP {{tp|p=29644010|t=2018. Value-based genomics |pdf=|usr=}}{{29644010}} gab.com Text Value-based genomics JO: Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=29644010 #FOAvip Advancements in next-generation sequencing have greatly enhanced the development of biomarker-driven cancer therapies. The affordability and availability of next-generation sequencers have allowed for the commercialization of next-generation sequencing platforms that have found widespread use for clinical-decision making and research purposes. Despite the greater availability of tumor molecular profiling by next-generation sequencing at our doorsteps, the achievement of value-based care, or improving patient outcomes while reducing overall costs or risks, in the era of precision oncology remains a looming challenge. In this review, we highlight available data through a pre-established and conceptualized framework for evaluating value-based medicine to assess the cost (efficiency), clinical benefit (effectiveness), and toxicity (safety) of genomic profiling in cancer care. We also provide perspectives on future directions of next-generation sequencing from targeted panels to whole-exome or whole-genome sequencing and describe potential strategies needed to attain value-based genomics. Twit Text FOAVip Value-based genomics ????Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=29644010 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29644010 #FOAvip English Wikipedia <ref>{{Cite pmid|29644010}}</ref> Value-based genomics #MMPMID29644010 Gong J; Pan K; Fakih M; Pal S; Salgia R Oncotarget 2018[Mar]; 9 (21): 15792-815 PMID29644010show ga Advancements in next-generation sequencing have greatly enhanced the development of biomarker-driven cancer therapies. The affordability and availability of next-generation sequencers have allowed for the commercialization of next-generation sequencing platforms that have found widespread use for clinical-decision making and research purposes. Despite the greater availability of tumor molecular profiling by next-generation sequencing at our doorsteps, the achievement of value-based care, or improving patient outcomes while reducing overall costs or risks, in the era of precision oncology remains a looming challenge. In this review, we highlight available data through a pre-established and conceptualized framework for evaluating value-based medicine to assess the cost (efficiency), clinical benefit (effectiveness), and toxicity (safety) of genomic profiling in cancer care. We also provide perspectives on future directions of next-generation sequencing from targeted panels to whole-exome or whole-genome sequencing and describe potential strategies needed to attain value-based genomics. äValue-based genomics (epmc).pdf DeepDyve Pubget Overpricing